December 2007 Volume 25 Number 12, pp 1329 - 1492
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0dXt0Eq
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0aAP0Eo
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BRQi0EM
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BkE0Eo
=====================================================================
Irresistibly easy protein, nucleic acid and cell isolation.
Dynabeads(R) Streptavidin beads are used in so many applications it's not always
easy to know which product is optimal for you. Our new trial kit includes 4 products to find the best for your work.
Try them at:
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biv30ES
=====================================================================
=====================================================================
Kelly Scientific Resources (KSR) is a highly specialized
division of Kelly Services, entirely committed to
placing qualified scientific and clinical research
professionals in positions across a full spectrum of
scientific disciplines and industries.
Looking for a new opportunity?
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BWYY0EJ
=====================================================================
=====================================================================
The University of Miami, Nature Publishing Group and Scripps Florida present
Miami 2008 Winter Symposium
Regulatory RNA in Biology and Human Health
February 2-6, 2008 * Miami Beach, FL
The 2008 symposium will look at our current understanding of the mechanisms of action and biogenesis of small regulatory RNAs and how this is being applied to create a new generation of therapeutics and diagnostics.
For more information visit: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BahG0EQ
a nature conference
=====================================================================
=====================================================================
Nature Biotechnology and Nature Reviews Drug Discovery present
Focus on Antivirals
This print and web focus comprehensively summarizes the science and business of antiviral drug R&D, highlighting innovative approaches and lessons learned from decades of antiviral drug development, as well as identifying key issues for future antiviral drug discovery and potential solutions.
To access this special focus visit: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Bh2H0Ee
Generously supported by principal sponsor Pfizer and supporting sponsor Gilead
=====================================================================
----------------------
EDITORIALS
----------------------
Stop the cull p1329
Animal vaccines prevent disease but founder because of political motivations.
doi:10.1038/nbt1207-1329
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biv40ET
Another inconvenient truth p1330
In Europe, no one apparently wants to listen if you have good news about genetically modified organisms (GMOs).
doi:10.1038/nbt1207-1330
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biv50EU
----------------------
NEWS
----------------------
Pfizer dumps Exubera pp1331 - 1332
George S. Mack
doi:10.1038/nbt1207-1331
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biv60EV
Proposed changes to patent code loom over biotech industry pp1333 - 1334
Amy Coombs
doi:10.1038/nbt1207-1333
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biv70EW
Biogen Idec goes on the auction block pp1335 - 1336
Randall Osborne and Mill Valley
doi:10.1038/nbt1207-1335
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biv80EX
Chinese manufacturers vie for piece of outsourcing pie pp1337 - 1338
Hepeng Jia
doi:10.1038/nbt1207-1337
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwA0Eh
IN BRIEF
News in brief pp1339 - 1340
doi:10.1038/nbt1207-1339
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwB0Ei
DATA PAGES
Biotech patents still strong p1341
Stacy Lawrence
doi:10.1038/nbt1207-1341
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwC0Ej
Pipelines turn to biotech p1342
Stacy Lawrence
doi:10.1038/nbt1207-1342
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwD0Ek
NEWS FEATURE
Biotech for your companion? pp1343 - 1345
With the market for companion animals and veterinary products booming, will the animal biotech sector finally receive the financial resources it has so long needed? Jim Kling reports.
Jim Kling
doi:10.1038/nbt1207-1343
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwE0El
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Best practices in patent license negotiations pp1347 - 1349
There's a lot to consider before out-licensing patent rights. Here, a law student and a seasoned patent attorney outline what every bioentrepreneur should know before tackling the task.
Jennifer Giordano-Coltart and Charles W Calkins
doi:10.1038/bioe.2007.5
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwF0Em
=====================================================================
LightCycler(R) 480 Real-Time PCR System
Speed up genetic variation discovery
Choose an integrated plate-based PCR / High Resolution Melting
platform with:
- Easy-to-use software
- Master mix with novel ResoLight DNA dye
- Oncogene analysis, methylation, and RNA editing data.
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC01RQ0EK
=====================================================================
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
GM soybeans - revisiting a controversial format pp1351 - 1354
Irina V. Ermakova
doi:10.1038/nbt1207-1351
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwG0En
GM soybeans - revisiting a controversial format pp1354 - 1355
Brian John
doi:10.1038/nbt1207-1354
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwH0Eo
GM soybeans - revisiting a controversial format p1355
Mae-Wan Ho and Peter T Saunders
doi:10.1038/nbt1207-1355a
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwI0Ep
GM soybeans - revisiting a controversial format p1355
Carlo Leifert
doi:10.1038/nbt1207-1355b
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwJ0Eq
GM soybeans - revisiting a controversial format pp1355 - 1356
Jack A Heinemann and Terje Traavik
doi:10.1038/nbt1207-1355c
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwK0Er
GM soybeans - revisiting a controversial format p1356
Joe Cummins
doi:10.1038/nbt1207-1356a
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwL0Es
Response to GM soybeans - revisiting a controversial format pp1356 - 1358
doi:10.1038/nbt1207-1356b
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwM0Et
Response to GM soybeans - revisiting a controversial format pp1359 - 1360
doi:10.1038/nbt1207-1359
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwN0Eu
COMMENTARY
Bridging the knowledge gaps in vaccine design pp1361 - 1366
To design the vaccines of the future we need to fully exploit microbial genomes and understand the basic mechanisms of the immune system.
Rino Rappuoli
doi:10.1038/nbt1207-1361
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwO0Ev
----------------------
NEWS AND VIEWS
----------------------
Fungal bioinsecticide with a sting pp1367 - 1368
A fungus engineered to express a scorpion toxin may prove useful in combating insect pests.
Matthew B Thomas and Andrew F Read
doi:10.1038/nbt1207-1367
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwP0Ew
Isotype selection in antibody engineering pp1369 - 1372
The properties of the different IgG isotypes should be considered in developing therapeutic antibodies.
Jochen G Salfeld
doi:10.1038/nbt1207-1369
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwQ0Ex
Research highlights p1373
doi:10.1038/nbt1207-1373
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwR0Ey
----------------------
EDITORIAL
----------------------
Beyond interferon p1375
Interferon (IFN)-[alpha] has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.
doi:10.1038/nbt1207-1375
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwS0Ez
----------------------
NEWS
----------------------
PROFILE
Ian Frazer p1377
Almost 15 years after Ian Frazer began the work that created the first vaccine to prevent cervical cancer caused by human papilloma virus (HPV), the 54-year-old immunologist is using his newfound prominence to educate others about treating HPV and to pass along the lessons he's learned about drug development.
Mark Ratner
doi:10.1038/nbt1207-1377
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwT0E1
NEWS FEATURE
Hepatitis C: staying the course pp1379 - 1381
A rash of failures for hepatitis C drugs, conflicting theories about the immune system's role and the looming issue of drug resistance make it impossible to predict when or how new therapies will make an impact. Ken Garber reports.
Ken Garber and Ann Arbor
doi:10.1038/nbt1207-1379
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwU0E2
----------------------
OPINION AND COMMENT
----------------------
COMMENTARY
Systems biology and the host response to viral infection pp1383 - 1389
Will our increasing understanding of virus-host interactions translate into a new generation of antiviral therapeutics or steer us toward an expensive journey to nowhere?
Seng-Lai Tan et al.
doi:10.1038/nbt1207-1383
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwV0E3
Antivirals - an increasingly healthy investment pp1390 - 1393
Continued investment from big pharma and a slew of new drugs with novel mechanisms of action are fueling investor interest in the antiviral space.
Brian McCarthy
doi:10.1038/nbt1207-1390
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwW0E4
----------------------
FEATURE
----------------------
Antivirals become a broader enterprise pp1395 - 1402
Small molecules have dominated antivirals for decades, but other approaches are needed and biologics could show the way.
Jeffrey L Fox
doi:10.1038/nbt1207-1395
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwX0E5
PATENTS
Patentability issues surrounding antivirals pp1403 - 1404
Although increased patenting has accompanied the development of antivirals as in vivo therapeutics, ongoing US litigation reflects concerns regarding their patentability.
Deborah L Lu, Angela M Collison and Thomas J Kowalski
doi:10.1038/nbt1207-1403
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwY0E6
Recent patent applications in antivirals p1405
doi:10.1038/nbt1207-1405
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0BiwZ0E7
----------------------
COMPUTATIONAL BIOLOGY
----------------------
COMMENTARY
Bioinformatics prediction of HIV coreceptor usage pp1407 - 1408
As sequencing technology and prediction algorithms improve, HIV genotyping and coreceptor usage prediction are likely to play an increasingly important role in guiding patient prognosis and treatment selection.
Thomas Lengauer et al.
doi:10.1038/nbt1371
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwa0EF
----------------------
RESEARCH
----------------------
PERSPECTIVE
Albinterferon [alpha]-2b: a genetic fusion protein for the treatment of chronic hepatitis C pp1411 - 1419
G Mani Subramanian et al.
doi:10.1038/nbt1364
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwb0EG
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwc0EH
REVIEW
The growth and potential of human antiviral monoclonal antibody therapeutics pp1421 - 1434
Wayne A Marasco and Jianhua Sui
doi:10.1038/nbt1363
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwd0EI
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwe0EJ
RNA interference against viruses: strike and counterstrike pp1435 - 1443
Joost Haasnoot, Ellen M Westerhout and Ben Berkhout
doi:10.1038/nbt1369
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwf0EK
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwg0EL
Genetic therapies against HIV pp1444 - 1454
John J Rossi, Carl H June and Donald B Kohn
doi:10.1038/nbt1367
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwh0EM
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwi0EN
BRIEF COMMUNICATION
A scorpion neurotoxin increases the potency of a fungal insecticide pp1455 - 1456
Chengshu Wang and Raymond J St Leger
doi:10.1038/nbt1357
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwj0EO
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwk0EP
ARTICLES
Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state pp1457 - 1467
Brian D Brown et al.
doi:10.1038/nbt1372
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwl0EQ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwm0ER
Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells pp1468 - 1475
Gabsang Lee et al.
doi:10.1038/nbt1365
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwn0ES
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwo0ET
LETTERS
Identification and targeting of the ROSA26 locus in human embryonic stem cells pp1477 - 1482
Stefan Irion et al.
doi:10.1038/nbt1362
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwp0EU
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwq0EV
Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes pp1483 - 1487
Marta Fernandez-Suarez et al.
doi:10.1038/nbt1355
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwr0EW
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biws0EX
ERRATA
Erratum: Funding crunch forces stem cell company to abandon therapies p1488
Monya Baker
doi:10.1038/nbt1207-1488a
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwt0EY
Erratum: Mice with a human touch p1488
Christopher Thomas Scott
doi:10.1038/nbt1207-1488b
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwu0EZ
Erratum: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria p1488
Russell P Rother et al.
doi:10.1038/nbt1207-1488c
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwv0Ea
CORRIGENDA
Corrigendum: A diverse family of thermostable cytochrome P450s created by recombination of stabilizing fragments p1488
Yougen Li et al.
doi:10.1038/nbt1207-1488d
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biww0Eb
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Management consulting for scientists pp1489 - 1490
Consultants can apply scientific thinking to solve complex business problems, often with immediate effects and tangible impact.
Samarth Kulkarni
doi:10.1038/nbt1207-1489
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwx0Ec
PEOPLE
People p1492
doi:10.1038/nbt1207-1492
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Biwy0Ed
=====================================================================
Evaluating Diagnostics: the VL guide
Effective diagnostics are a crucial element of successful infectious disease management, yet their development and use, particularly in the developing world, remains a neglected area. To address this deficiency, TDR and Nature Reviews Microbiology have joined forces to produce a series of user-friendly diagnostic evaluation guides.
The focus of the third guide is visceral leishmaniasis. Access the guide FREE online at
www.nature.com/nrmicro/supplements
Produced in collaboration with TDR
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/eh4X0Xztnp0HjC0Zzu0EH
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2007 Nature Publishing Group
=====================================================================
